Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects.


Journal

Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637

Informations de publication

Date de publication:
01 07 2022
Historique:
received: 16 07 2021
revised: 06 12 2021
accepted: 27 04 2022
pubmed: 26 5 2022
medline: 6 7 2022
entrez: 25 5 2022
Statut: ppublish

Résumé

T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.

Identifiants

pubmed: 35612500
pii: 699213
doi: 10.1158/2326-6066.CIR-21-0568
doi:

Substances chimiques

Lipocalins 0
Interleukin-4 207137-56-2
Intramolecular Oxidoreductases EC 5.3.-
prostaglandin R2 D-isomerase EC 5.3.99.2
Prostaglandin D2 RXY07S6CZ2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

900-916

Informations de copyright

©2022 American Association for Cancer Research.

Auteurs

Romain Mary (R)

Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.
LipSTIC LabEx, Dijon, France.

Fanny Chalmin (F)

CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.
LipSTIC LabEx, Dijon, France.

Théo Accogli (T)

Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.
LipSTIC LabEx, Dijon, France.

Mélanie Bruchard (M)

Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.
LipSTIC LabEx, Dijon, France.
Centre Georges François Leclerc, Dijon, France.

Christophe Hibos (C)

Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.
LipSTIC LabEx, Dijon, France.

Joséphine Melin (J)

LipSTIC LabEx, Dijon, France.
Centre Georges François Leclerc, Dijon, France.

Caroline Truntzer (C)

Centre Georges François Leclerc, Dijon, France.

Emeric Limagne (E)

Centre Georges François Leclerc, Dijon, France.

Valentin Derangère (V)

Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Centre Georges François Leclerc, Dijon, France.

Marion Thibaudin (M)

Centre Georges François Leclerc, Dijon, France.

Etienne Humblin (E)

CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.
Precision Immunology Institute, New York, New York.

Romain Boidot (R)

Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Centre Georges François Leclerc, Dijon, France.

Sandy Chevrier (S)

Centre Georges François Leclerc, Dijon, France.

Laurent Arnould (L)

Centre Georges François Leclerc, Dijon, France.

Corentin Richard (C)

Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Centre Georges François Leclerc, Dijon, France.

Quentin Klopfenstein (Q)

Centre Georges François Leclerc, Dijon, France.

Antoine Bernard (A)

Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.
LipSTIC LabEx, Dijon, France.

Yoshihiro Urade (Y)

Intemational Institute for Integrative Sleep Medicine, University of Tsukuba, Tsukuba, Japan.

James A Harker (JA)

National Heart & Lung Institute, Imperial College London, London, United Kingdom.

Lionel Apetoh (L)

Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.
LipSTIC LabEx, Dijon, France.

François Ghiringhelli (F)

Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.
LipSTIC LabEx, Dijon, France.
Centre Georges François Leclerc, Dijon, France.

Frédérique Végran (F)

Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.
LipSTIC LabEx, Dijon, France.
Centre Georges François Leclerc, Dijon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH